Evidence map›Paper›PMID 40978637›Full record

ArticleBioinformation2025

A review on mTOR inhibitor use and outcomes of COVID-19 among patients with kidney transplantation.

Sawai Singh Rathore, Vanessa Vidaurre Corrales, Ashwin Hassan Gopala, Hamam Aneis, Ibrahim Marouf Yasin Al Shyyab, Mutaz AlBeetar, Samah Mohamed Kannas, Omar Jihad Saleh Almistarihi, Mohamed Hamed Daoud

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sawai Singh RathoreDepartment of Internal Medicine, Dr. Sampurnanand Medical College, Jodhpur, Rajasthan, India.
Vanessa Vidaurre CorralesDepartment of Internal Medicine, Universidad Privada del Valle, Cochabamba, Bolivia.
Ashwin Hassan GopalaDepartment of Internal Medicine, Jinzhou Medical College, Jinzhou, China.
Hamam AneisDepartment of Internal Medicine, UPMC, Mckeesport, Pennsylvania.
Ibrahim Marouf Yasin Al ShyyabDepartment of Internal Medicine, University of Sharjah, Sharjah, UAE.
Mutaz AlBeetarDepartment of Internal Medicine, University of Sharjah, Sharjah, UAE.
Samah Mohamed KannasDepartment of Internal Medicine, University of Sharjah, Sharjah, UAE.
Omar Jihad Saleh AlmistarihiDepartment of Internal Medicine, Fakeeh University Hospital, Dubai, UAE.
Mohamed Hamed DaoudDepartment of Internal Medicine, Bogomolets National Medical University, Kyiv, Ukraine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney transplant recipients are at increased risk of severe COVID-19 due to immunosuppression and the impact of mTOR inhibitors on outcomes remains unclear. Hence, we evaluated 24 observational studies with 5,882 kidney transplant patients to assess the association of mTOR inhibitors with COVID-19 severity and mortality. Random-effects models showed that mTOR inhibitors were significantly associated with reduced mortality (OR=0.63, 95% CI 0.48-0.83, P=0.001) but not with COVID-19 severity (OR=0.70, 95% CI 0.41-1.20, P=0.865). Thus, mTOR inhibitors may provide a survival benefit in kidney transplant patients with COVID-19, highlighting the need for further research.

Indexed as

COVID-19everolimushospitalizationICU admissionirolimusKidney transplantmortalitymTOR inhibitorsrenal transplantSARS-CoV-2temsirolimus

Identifiers

PMID40978637
PMCPMC12449486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.